Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLS2401 Injection in Participants With Advanced Prostate Cancer

NCT07869888 is registered in ClinicalTrials.gov with Shanghai Qilu Pharmaceutical Research and Development Center LTD as lead sponsor.

NCT NCT07869888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLS2401 Injection in Participants With Advanced Prostate Cancer
Lead sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 6, 2026
Completion date
March 30, 2029
Enrollment
252 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer